How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/multimodal-acetaminophen-gabapentin-ketamine-bupivacaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine (multimodal:acetaminophen, gabapentin, ketamine, bupivacaine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multimodal analgesic combination. Area: Pain Management.

marketed Multimodal analgesic combination Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine (multimodal:acetaminophen, gabapentin, ketamine, bupivacaine) — University of Wisconsin, Madison. This multimodal formulation combines four analgesic and anesthetic agents with distinct mechanisms to provide synergistic pain relief through multiple pathways.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
multimodal:acetaminophen, gabapentin, ketamine, bupivacaine TARGET	multimodal:acetaminophen, gabapentin, ketamine, bupivacaine	University of Wisconsin, Madison	marketed	Multimodal analgesic combination
ropivacaine,morphine chloride,epinephrine,ketorolac	ropivacaine,morphine chloride,epinephrine,ketorolac	Jose Antonio Bernia Gil	marketed	Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic)	Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac)
baclofen/amitriptyline/ketamine gel	baclofen/amitriptyline/ketamine gel	Alliance for Clinical Trials in Oncology	phase 3	Multimodal analgesic combination gel	GABA-B receptor, norepinephrine/serotonin transporters, NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multimodal analgesic combination class)

University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). multimodal:acetaminophen, gabapentin, ketamine, bupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/multimodal-acetaminophen-gabapentin-ketamine-bupivacaine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab